FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387208864> ?p ?o ?g. }

• W4387208864 endingPage "e156" @default.
• W4387208864 startingPage "e156" @default.
• W4387208864 abstract "Stereotactic body radiation therapy (SBRT) offers an important treatment option for metastatic liver tumors. The introduction of magnetic resonance (MR) guided SBRT has paved the way for optimal tumor visualization and daily plan adaptation. The purpose of this study is to review tolerability of MR-guided SBRT of liver metastases and to present early toxicity and quality of life outcomes.All patients with liver metastases who were treated on a 1.5T MR-Linac and enrolled in the MOMENTUM study (NTC04075305) were included. Patients were treated between April 2019 and December 2022 in 5 different institutes across 3 countries. Descriptive statistics were used to present the tolerability of treatment, toxicity (CTCAE v5.0) and quality of life outcomes (QLQ C30 and EQ 5D-5L) at baseline and 3 months after treatment.A total of 127 patients with liver metastases were included in the analysis. There were 64 females and 63 men, with a median age of 66 years (range 31 to 93). The median ECOG-score was 0 (range 0-2). The most common primary origin was colorectal cancer (66%), followed by bronchus and lung cancer (12%), with ocular melanoma, pancreatic and breast cancer being joint third (all 6-7%). Fractionation schedules ranged from 12 - 67.5 Gy in 2 - 12 fractions. The most commonly prescribed fractionation dose was 60 Gy in 3-5 fractions (53% and 13% respectively) and 50 Gy in 5 fractions (11%). Completion data was available for 116 patients. 112 patients (97%) received all fractions. 4 Patients (3%) did not complete treatment due to technical issues and 2 of the 4 receiving no treatment on the MR-Linac. Physician reported toxicity at 3 months was recorded for 82 patients (66%). No grade 4 or 5 toxicities were reported. There were 12 grade 3 toxicities reported in 6 (7%) patients with 5 deemed radiation therapy related (Table 1) and 34 grade 2 toxicities in 21 (26%) patients.We have presented the largest cohort (to our knowledge) of 127 patients treated using 1.5 Tesla MR Guidance for metastatic liver tumors. 97% of treatments were completed successfully with all treatments being well tolerated. Acute grade 3 toxicity was reported in 7% of patients with no grade 4 or 5 toxicities present. These outcomes suggest radiotherapy on the MR-Linac is a safe and promising treatment for patients with liver metastases. Additional prospective follow up is ongoing for late toxicity events and long-term control data. Table 1: Grade ≥3 toxicity at 3 months related to radiation therapy (total No. of patients was 82) There was QLQ-C30 data on 89 patients at baseline and on 62 patients at 3 months. At 3 months the median score was worse for physical functioning, VAS score and pain." @default.
• W4387208864 created "2023-09-30" @default.
• W4387208864 creator A5006174923 @default.
• W4387208864 creator A5021970576 @default.
• W4387208864 creator A5024252015 @default.
• W4387208864 creator A5027012956 @default.
• W4387208864 creator A5036821548 @default.
• W4387208864 creator A5046180969 @default.
• W4387208864 creator A5058395730 @default.
• W4387208864 creator A5058970658 @default.
• W4387208864 creator A5059043243 @default.
• W4387208864 creator A5059953815 @default.
• W4387208864 creator A5069595542 @default.
• W4387208864 creator A5070115702 @default.
• W4387208864 creator A5071798797 @default.
• W4387208864 creator A5086357504 @default.
• W4387208864 creator A5087851185 @default.
• W4387208864 date "2023-10-01" @default.
• W4387208864 modified "2023-10-17" @default.
• W4387208864 title "Outcomes of Tolerability, Acute Toxicity and Quality of Life from MR-Guided Radiation Therapy (1.5T MR-Linac) for Liver Metastases in the MOMENTUM Study" @default.
• W4387208864 doi "https://doi.org/10.1016/j.ijrobp.2023.06.981" @default.
• W4387208864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784746" @default.
• W4387208864 hasPublicationYear "2023" @default.
• W4387208864 type Work @default.
• W4387208864 citedByCount "0" @default.
• W4387208864 crossrefType "journal-article" @default.
• W4387208864 hasAuthorship W4387208864A5006174923 @default.
• W4387208864 hasAuthorship W4387208864A5021970576 @default.
• W4387208864 hasAuthorship W4387208864A5024252015 @default.
• W4387208864 hasAuthorship W4387208864A5027012956 @default.
• W4387208864 hasAuthorship W4387208864A5036821548 @default.
• W4387208864 hasAuthorship W4387208864A5046180969 @default.
• W4387208864 hasAuthorship W4387208864A5058395730 @default.
• W4387208864 hasAuthorship W4387208864A5058970658 @default.
• W4387208864 hasAuthorship W4387208864A5059043243 @default.
• W4387208864 hasAuthorship W4387208864A5059953815 @default.
• W4387208864 hasAuthorship W4387208864A5069595542 @default.
• W4387208864 hasAuthorship W4387208864A5070115702 @default.
• W4387208864 hasAuthorship W4387208864A5071798797 @default.
• W4387208864 hasAuthorship W4387208864A5086357504 @default.
• W4387208864 hasAuthorship W4387208864A5087851185 @default.
• W4387208864 hasConcept C126322002 @default.
• W4387208864 hasConcept C126838900 @default.
• W4387208864 hasConcept C155806632 @default.
• W4387208864 hasConcept C197934379 @default.
• W4387208864 hasConcept C2778120868 @default.
• W4387208864 hasConcept C2778375690 @default.
• W4387208864 hasConcept C2780149145 @default.
• W4387208864 hasConcept C2780387249 @default.
• W4387208864 hasConcept C29730261 @default.
• W4387208864 hasConcept C2989005 @default.
• W4387208864 hasConcept C509974204 @default.
• W4387208864 hasConcept C71924100 @default.
• W4387208864 hasConceptScore W4387208864C126322002 @default.
• W4387208864 hasConceptScore W4387208864C126838900 @default.
• W4387208864 hasConceptScore W4387208864C155806632 @default.
• W4387208864 hasConceptScore W4387208864C197934379 @default.
• W4387208864 hasConceptScore W4387208864C2778120868 @default.
• W4387208864 hasConceptScore W4387208864C2778375690 @default.
• W4387208864 hasConceptScore W4387208864C2780149145 @default.
• W4387208864 hasConceptScore W4387208864C2780387249 @default.
• W4387208864 hasConceptScore W4387208864C29730261 @default.
• W4387208864 hasConceptScore W4387208864C2989005 @default.
• W4387208864 hasConceptScore W4387208864C509974204 @default.
• W4387208864 hasConceptScore W4387208864C71924100 @default.
• W4387208864 hasIssue "2" @default.
• W4387208864 hasLocation W43872088641 @default.
• W4387208864 hasLocation W43872088642 @default.
• W4387208864 hasOpenAccess W4387208864 @default.
• W4387208864 hasPrimaryLocation W43872088641 @default.
• W4387208864 hasRelatedWork W1983863207 @default.
• W4387208864 hasRelatedWork W2013843382 @default.
• W4387208864 hasRelatedWork W2093044092 @default.
• W4387208864 hasRelatedWork W2292349525 @default.
• W4387208864 hasRelatedWork W3031853862 @default.
• W4387208864 hasRelatedWork W3086650356 @default.
• W4387208864 hasRelatedWork W3214062064 @default.
• W4387208864 hasRelatedWork W4283380970 @default.
• W4387208864 hasRelatedWork W4387206995 @default.
• W4387208864 hasRelatedWork W4387208864 @default.
• W4387208864 hasVolume "117" @default.
• W4387208864 isParatext "false" @default.
• W4387208864 isRetracted "false" @default.
• W4387208864 workType "article" @default.